Answers are grounded in this paper and cite their sources.
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), in which current therapies incompletely correct skeletal disease because enzyme delivery to avascular cartilage is limited. We developed a dual-lineage ex vivo gene-editing strategy combining murine hematopoietic stem/progenitor cells (mHSPCAAVS1) and rapidly expanding clonal human mesenchymal stem cells (REC-MSCs), using an integrase-defective lentiviral (IDLV) CRISPR/Cas9 platform designed to deliver a GALNS cassette to the AAVS1 safe-harbor locus. Nocodazole-mediated G2/M synchronization further increased GALNS output in HDR-competent conditions. Edited REC-MSCs showed supraphysiological GALNS production and secretion, and edited mHSPCAAVS1 reached approximately 13.9-fold wild-type activity; enhanced expression persisted at 30 days post-transduction. In non-contact transwell co-culture, edited REC-MSCs and edited mHSPCAAVS1 each increased GALNS activity in MPS IVA patient fibroblasts, and combined exposure produced the greatest correction, reducing lysosomal mass by ~36%, mono-sulfated keratan sulfate by ~54%, and mitochondrial superoxide toward wild-type levels at 30 days. Irradiated REC-MSC feeder layers supported 2.59-fold mHSPCAAVS1 expansion and a 1.96-fold higher proportion of EGFP-positive cells. Cross-correction was therefore achieved by each lineage and was greatest in combination, establishing a functional basis for in vivo evaluation of this dual-lineage strategy in MPS IVA.
No takes yet. Share an insight, caveat, or question.
Nidhi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: